In controlled clinical trials of essential hypertension, dizziness was the only drug related side effect that occurred with an incidence greater than placebo in 1% or more of patients treated with Losartan. In addition, dose-related orthostatic effects were seen in less than 1% of patients. Rarely, rash was reported, although the incidence in controlled clinical trials was less than placebo. In contrast to ACE inhibitors, Losartan is not found to cause accumulation of bradykinin and so incidence of cough observed with Losartan is significantly less as compared to ACE Inhibitors and is not more than that observed with placebo in several clinical trials.
View ADR Monitoring Form